Silence Therapeutics says divesiran met Phase 2 primary endpoint in polycythemia vera
Silence Therapeutics reported positive topline results from the 36-week Phase 2 SANRECO trial of divesiran in 48 phlebotomy-dependent patients with polycythemia vera, meeting its primary and key secondary endpoints. The company expects to start a Phase 3 trial of divesiran at Q12W dosing versus placebo in the first half of 2027, a step that advances its lead candidate toward potential approval, though the filing reports no revenue, profit or financing figures.
Key points
- Primary endpoint response rate was 88% for divesiran versus 19% for placebo (p<0.0001)
- Mean phlebotomies per patient were 0.2 for divesiran versus 2.1 for placebo over weeks 0-36 (p<0.0001)
- Phase 3 trial of divesiran at Q12W versus placebo expected to start in the first half of 2027
- Divesiran was well tolerated with no new safety findings; two investigator-reported grade 1 anemia cases
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.